Jordi Roig retweetledi

Nutcracker syndrome in 2026:
a nephrologist-oriented diagnosis and management
doi.org/10.1093/ckj/sf…

English
Jordi Roig
997 posts




























🟢Kerendia™ (finerenone) approved in 🇪🇺 is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate statistically significant and clinically meaningful cardiovascular benefits in a Phase III study in patients with HF with LVEF ≥40%







